MedTrace Logo

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

NCT05349643 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-07-05

No results posted yet for this study

Summary

AMB-051-07 is an open-label, adaptive, dose-ranging study with long-term extension in adults with tenosynovial giant cell tumor

Conditions

  • Pigmented Villonodular Synovitis
  • TGCT
  • Tenosynovial Giant Cell Tumor

Interventions

BIOLOGICAL

AMB-05X

A fully human monoclonal immunoglobulin (IgG2) directed against c-fms

Sponsors & Collaborators

  • AmMax Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Dorothy Nguyen, MD · AmMax Bio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-26
Primary Completion
2024-06-03
Completion
2024-06-03
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05349643 on ClinicalTrials.gov